Ratio between PlGF and Flt-1 as a prognostic tool for cardiovascular diseases
INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH
The invention uses the significance of the biochemical markers PlGF and Flt-1 for risk stratification of people with a cardiovascular disease or for the evaluation to develop such a disease.
The method involves the quantification and calculation of the ratio of PlGF / Flt-1 in a sample derived from the patient by means of a diagnostic kit. In addition to risk stratification a therapy-monitoring is possible.
PlGF and Flt-1 are known biochemical markers for the determination of various diseases including those of the cardiovascular system. However, state of the art methods do not consider the relationship of both markers and their dependable key functions especially in the field of cardiovascular diseases with atherosclerotic etiology. Both markers are dependent on each other and control the progress of a cardiovascular disease, or rather determine the development of such.
The method allows the determination of a possible illness, as well as diagnosis and monitoring of the cardiovascular disease. The method can especially be applied on coronary heart diseases (angina pectoris, acute myocardial infarction), cerebrovascular disease and peripheral occlusive arterial disease.
The inventive diagnostic kit consists of the analytical materials for determining 2 or 3 biochemical markers as well as interpretations guidelines and therapy suggestions. Parts of PlGF and Flt-1 (like peptides) can be analysed. Alternatively the mRNA of both markers can be determined. Additionally, the method can be extended to analyse further markers, like VEGF, sCD40L, PAPP-A, MPO, BNP or NT-proBNP. Therefore an additional specification of the method is possible (applica-tion on 3 markers altogether).
The quantification of the markers is done by known immunological methods like the ELISA.
The samples can be pretreated. Peripheral blood samples, blood plasma and serum can be used for the analysis. Alternatively tissue samples can be used as well.
Reference samples or defined reference values are taken to evaluate the risk of the disease.
The quantification of the marker can be done by defining the concentration or number of molecules depending on the kind of sample used for analysis.
The method has already been tested in a clinical trial.
A German patent application is filed.
Owner of patent
Johann Wolfgang Goethe-University Frankfurt am Main
Licensing of the technology is possible.